Overview / Abstract: |
This CME Touchpoint digital newsletter is a great way to bring clinicians up to date on the guideline recommendations for the selection of antimicrobial therapy when treating initial and recurrent C. difficile infection. Dr. Feuerstadt and Dr. Khanna review the latest clinical trial data and treatment guidelines for C. difficile infection. The digital newsletter includes text-based content, faculty video commentary, graphics, and supplemental resources. The Centers for Disease Control and Prevention continues to classify C. difficile as an urgent threat given the great burden on patients and the healthcare system. This Gram-positive bacterium causes diarrhea, abdominal bloating, and colitis in addition to significant morbidity and mortality, increased healthcare costs, and hospital readmission rates. In response to accumulating clinical trial evidence and real-world data, guideline recommendations on the selection of antimicrobial therapy have changed. Clinicians may not be familiar with these changes in the selection and application of antimicrobial therapies for treating initial and recurrent CDI. |
Expiration |
Apr 14, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online |
Credits / Hours |
1.0 AMA PRA Category 1 Credit™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Paul Feuerstadt, MD, FACG, AGAF Sahil Khanna, MBBS, MS, FACG |
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Merck & Co., Inc. |
Keywords / Search Terms |
ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Newsletter, C. difficile, CME, ACG, Dr. Feuerstadt, Dr. Khanna, gut microbiome, recurrent, infections, infectious disease, gastroenterology, physician, pharmacists, live symposium, microbiota restoration therapy, fidaxomicin, IDSA/SHEA, bezlotoxumab, vancomycin Free CE CME |